Clinical Studies on Abdominal Aortic Aneurysm Treatments: A Review
I. Introduction
Abdominal Aortic Aneurysm (AAA) is a serious medical condition characterized by a localized enlargement of the abdominal aorta, the main blood vessel supplying blood to the lower body. The prevalence of AAA increases with age, and rupture of an AAA is often fatal. Effective management strategies are crucial to prevent rupture and improve patient outcomes. Treatment approaches for AAA range from watchful waiting and medical management to surgical interventions, including open surgical repair (OSR) and endovascular aneurysm repair (EVAR). This blog post aims to provide a comprehensive review of clinical studies on various AAA treatments, offering insights into their efficacy, safety, and evolving landscape. It is important to note that this article is for informational purposes only and does not constitute medical advice. Readers should consult with a qualified healthcare professional for any medical concerns.
II. Medical Management of AAA
Medical management plays a vital role in patients with small AAAs or those deemed unfit for surgical intervention. The primary goal of pharmacotherapy in AAA is to limit aneurysm growth and reduce the risk of rupture. Various drug classes have been investigated for their potential to achieve this, including anti-inflammatories, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and statins. Clinical trials have explored the efficacy of these agents. For instance, studies on doxycycline have shown promise in inhibiting AAA progression by targeting matrix metalloproteinases, which are involved in aortic wall degradation [5]. However, the overall evidence for significant pharmacological reduction in AAA growth remains mixed, and ongoing research continues to explore new therapeutic targets and refine existing strategies. Regular monitoring and surveillance with imaging techniques are essential components of medical management to track aneurysm size and identify any rapid expansion that may necessitate intervention.
III. Endovascular Aneurysm Repair (EVAR)
Endovascular Aneurysm Repair (EVAR) has revolutionized AAA treatment, offering a less invasive alternative to traditional open surgery. The procedure involves inserting a stent-graft through small incisions in the groin, which is then deployed within the aorta to reinforce the weakened vessel wall and exclude the aneurysm from blood flow. Clinical studies have consistently demonstrated that EVAR is associated with lower perioperative mortality compared to OSR [13, 14]. For example, one study reported significantly lower 1-year mortality for EVAR (2%) compared to OSR (14%) [14].
However, the long-term outcomes of EVAR require careful consideration. While EVAR offers immediate benefits, it is associated with a higher rate of re-interventions due to complications such as endoleaks, device migration, or graft material fatigue [12]. A study comparing long-term outcomes of open versus endovascular repair found that open repair was associated with significantly lower 6-year mortality (35.6%) compared with endovascular repair (41.2%) [12]. This highlights the importance of lifelong surveillance for EVAR patients. Advances in EVAR technology, including newer generation stent-grafts and fenestrated/branched devices, are expanding the applicability of EVAR to more anatomically complex AAAs, further improving patient selection and outcomes.
IV. Open Surgical Repair (OSR)
Open Surgical Repair (OSR) remains the gold standard for AAA treatment, particularly for younger, healthier patients and those with complex aortic anatomies unsuitable for EVAR. This traditional approach involves a large abdominal incision to directly access and repair the aneurysm with a synthetic graft. While OSR is associated with higher perioperative morbidity and mortality compared to EVAR [13, 14], it offers excellent long-term durability and a lower rate of re-interventions. The decision between OSR and EVAR is complex and depends on various factors, including patient comorbidities, aneurysm morphology, and surgeon expertise. For patients with suitable anatomy and good surgical risk, OSR provides a definitive repair with proven long-term success.
V. Emerging Therapies and Future Directions
The field of AAA treatment is continuously evolving, with significant research efforts focused on developing novel therapies and refining existing ones. Emerging therapies include stem cell-based approaches, which aim to promote aortic wall regeneration and reduce aneurysm progression. Preclinical models have shown promising results, and several clinical trials are underway to assess the safety and efficacy of stem cell therapies in humans [2, 7].
Furthermore, research into novel drug targets and pharmacogenomics is paving the way for more personalized medicine approaches [1, 6]. Understanding the genetic predispositions and molecular pathways involved in AAA development could lead to targeted pharmacological interventions. Ongoing clinical trials at institutions like UCSD and UCSF are exploring new devices, techniques, and medical therapies for AAA, underscoring the dynamic nature of this field [9, 10]. These advancements hold the potential to further improve outcomes and expand treatment options for patients with AAA.
VI. Conclusion
The management of Abdominal Aortic Aneurysm has witnessed remarkable progress, with both medical management and surgical interventions playing crucial roles. While EVAR offers a less invasive option with lower perioperative risks, OSR remains a durable solution for suitable patients. The continuous development of emerging therapies and personalized medicine approaches promises a future with even more effective and tailored treatments for AAA. The importance of individualized patient care, considering each patient's unique clinical profile and preferences, cannot be overstated in determining the most appropriate treatment strategy.
VII. Disclaimer
This article is for informational purposes only and does not constitute medical advice. The content provided herein is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this article.
VIII. References
- [1] Alsabbagh, Y. (2024). Personalized Medicine - Abdominal Aortic Aneurysm ... *pmc.ncbi.nlm.nih.gov*
- [2] Badawy, S. (2025). Stem cell-based therapies for treatment of abdominal aortic ... *nature.com*
- [3] Chen, J. (2024). Medical treatments for abdominal aortic aneurysm. *tandfonline.com*
- [4] Phie, J. (2021). Systematic Review and Meta-Analysis of Interventions to ... *ahajournals.org*
- [5] Su, Z. (2022). Pharmacotherapy in Clinical Trials for Abdominal Aortic ... *pmc.ncbi.nlm.nih.gov*
- [6] Golledge, J. (2023). Pathogenesis and management of abdominal aortic aneurysm. *academic.oup.com*
- [7] Badawy, S. (2025). Stem cell-based therapies for treatment of abdominal aortic ... *pmc.ncbi.nlm.nih.gov*
- [8] Mayo Clinic. (n.d.). Aortic Aneurysm Clinical Trials. *mayo.edu*
- [9] UCSD. (2026). UCSD Abdominal Aortic Aneurysm Clinical Trials for 2026. *clinicaltrials.ucsd.edu*
- [10] UCSF. (2025). UCSF Abdominal Aortic Aneurysm Clinical Trials for 2026. *clinicaltrials.ucsf.edu*
- [11] MUSC. (2025). MUSC study seeks drug target to treat small abdominal ... *musc.edu*
- [12] Yei, K. (2022). Long-term Outcomes of Open vs Endovascular Abdominal ... *jamanetwork.com*
- [13] Lederle, F. A. (2019). Open versus Endovascular Repair of Abdominal Aortic ... *nejm.org*
- [14] Cherian, A. M. (2024). Outcomes of Endovascular Aneurysm Repair (EVAR ... *pmc.ncbi.nlm.nih.gov*
- [15] Zlatanovic, P. (2023). Short Term and Long Term Clinical Outcomes of ... *sciencedirect.com*